
## Aminobenzenesulfonic auristatin E-d<sub>8</sub>

**MedChemExpress** 

Cat. No.:	HY-145989S
Molecular Formula:	C <sub>37</sub> H <sub>56</sub> D <sub>8</sub> N <sub>6</sub> O <sub>8</sub> S
Molecular Weight:	761.05
Target:	Drug-Linker Conjugates for ADC; Microtubule/Tubulin
Pathway:	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Storage:	<b>4°C, protect from light</b> * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



BIOLOGICAL ACTIVITY	
BIOLOGICAL ACTIVITY	
Description	Aminobenzenesulfonic auristatin E-d <sub>8</sub> is the deuterium labeled Aminobenzenesulfonic auristatin E. Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic[1][2].
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Kevin HAMBLETT, et al. Anti-her2 biparatopic antibody-drug conjugates and methods of use. Patent WO2019173911A1.

[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898Fax: 609-228-5909E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA